SCHEMBL1193532

SCHEMBL1193532

COc1cc2c(cc1OC)CN(C(=O)Cl)CC2

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.63
KMT2A Q03164 5/20 0.62
MEN1 O00255 4/20 0.62
HRH3 Q9Y5N1 1/20 0.60
KDM4E B2RXH2 3/20 0.59
HSD17B10 Q99714 3/20 0.59
ALOX15 P16050 1/20 0.59
NPC1 O15118 1/20 0.59
THRB P10828 1/20 0.59
MAPT P10636 2/20 0.58
ALDH1A1 P00352 2/20 0.58
GAA P10253 1/20 0.58
MDM2 Q00987 1/20 0.58
POLB P06746 1/20 0.57
NPSR1 Q6W5P4 1/20 0.56
ATM Q13315 1/20 0.56
MAOA P21397 1/20 0.56
MAOB P27338 1/20 0.56
SLC6A4 P31645 1/20 0.56
TSHR P16473 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4243284 0.92 MAPK1 (0.56) MAPK1KMT2AMEN1HRH3KDM4E
SCHEMBL2873071 0.85 MAPK1 (0.65) MAPK1KMT2AMEN1HRH3KDM4E
SCHEMBL7006650 0.85 MAPK1 (0.65) MAPK1KMT2AMEN1HRH3KDM4E
SCHEMBL5467759 0.84 KMT2A (0.64) MAPK1KMT2AMEN1HRH3KDM4E
SCHEMBL10804729 0.83 KDM4E (0.65) MAPK1KMT2AMEN1HRH3KDM4E
SCHEMBL22196923 0.83 KMT2A (0.66) MAPK1KMT2AMEN1HRH3KDM4E
SCHEMBL10799287 0.82 HRH3 (0.62) MAPK1KMT2AMEN1HRH3KDM4E
SCHEMBL14996180 0.81 KMT2A (0.67) MAPK1KMT2AMEN1HRH3KDM4E
SCHEMBL21255989 0.80 ESR1 (0.69) MAPK1KMT2AMEN1HRH3KDM4E
SCHEMBL21255890 0.80 KMT2A (0.66) MAPK1KMT2AMEN1HRH3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2220060-B1 TETRAHYDROBENZOTHIAZOLE DERIVATIVES MOTAC NEUROSCIENCE LTD (GB) 2016-09-14 EP disclosed
US-8389555-B2 Medicaments MOTAC NEUROSCIENCE LIMITED (GB) 2013-03-05 US disclosed
US-20110046153-A1 Medicaments MOTAC NEUROSCIENCE LIMITED (GB) 2011-02-24 US disclosed
EP-2220060-A1 MEDICAMENTS Motac Neuroscience Limited (GB) 2010-08-25 EP disclosed
WO-2009056805-A1 MEDICAMENTS MOTAC NEUROSCIENCE LIMITED (GB) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046153-A1 Medicaments MTNR1A, SIGMAR1, OPRK1 MAPK1 3615/4885KMT2A 3354/4885MEN1 590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.